Literature DB >> 6360692

Pharmacokinetic aspects of guanfacine withdrawal syndrome in a hypertensive patient with chronic renal failure.

J R Kiechel, D Lavene, M Guerret, E Comoy, M Godin, J P Fillastre.   

Abstract

The unusual observation of a withdrawal syndrome due to guanfacine in a hypertensive patient with chronic renal failure led to a study of the kinetics of the drug in this patient. The principal pharmacokinetic parameters of guanfacine were greatly altered, with extended biotransformation and a decrease in the half-life compared to the values observed in other cases of severe renal insufficiency. Associated treatment with phenobarbital had had a considerable effect, as shown by the results of a further kinetic study 2 months after withdrawal of the phenobarbital. The findings then were in good agreement with reference values which strongly suggests a consequence of the enzyme inducing effect of phenobarbital. Advice about the dosage regimen in such cases is given.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6360692     DOI: 10.1007/bf00542112

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Pharmacology of BS 100-141, a centrally acting antihypertensive drug.

Authors:  K Saameli; G Scholtysik; R Waite
Journal:  Clin Exp Pharmacol Physiol       Date:  1975       Impact factor: 2.557

2.  Clinical experience with guanfacine in long-term treatment of hypertension. Part II: adverse reactions to guanfacine.

Authors:  P Jerie
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

Review 3.  Pharmacokinetics and metabolism of guanfacine in man: a review.

Authors:  J R Kiechel
Journal:  Br J Clin Pharmacol       Date:  1980       Impact factor: 4.335

4.  Determination of 3-hydroxy-guanfacine in biological fluids by electron-capture gas-liquid chromatography.

Authors:  M Guerret; C Julien-Larose; J R Kiechel; D Lavène
Journal:  J Chromatogr       Date:  1982-12-10

5.  Determination of guanfacine in biological fluids by electron-capture GLC.

Authors:  M Guerret; D Lavene; J Longchampt; J L Kiger
Journal:  J Pharm Sci       Date:  1979-02       Impact factor: 3.534

6.  [Pharmacokinetic study of guanfacine in patients with renal insufficiency and in patients under chronic dialysis (author's transl)].

Authors:  J R Kiechel; D Lavene; M Gurret; J Coustenoble; M Petrover; M Godin; J P Fillastre
Journal:  Nephrologie       Date:  1980
  6 in total
  2 in total

Review 1.  Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.

Authors:  Georgios Schoretsanitis; Jose de Leon; Chin B Eap; John M Kane; Michael Paulzen
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

Review 2.  Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.

Authors:  E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.